Related references
Note: Only part of the references are listed.Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer
S. B. Campbell et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Improved Renal Function After Early Conversion From a Calcineurin Inhibitor to Everolimus: a Randomized Trial in Kidney Transplantation
L. Mjornstedt et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation
Sylvie Euvrard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Interim Results from an Open-Label Study of Planned Transition from Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Cardiovascular Safety
H. Tedesco-Silva et al.
TRANSPLANTATION (2012)
Chronic renal allograft injury: early detection, accurate diagnosis and management
Julio Pascual et al.
TRANSPLANTATION REVIEWS (2012)
The Relationship Between Kidney Function and Long-term Graft Survival After Kidney Transplant
Bertram L. Kasiske et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2011)
The ORION Study: Comparison of Two Sirolimus-Based Regimens versus Tacrolimus and Mycophenolate Mofetil in Renal Allograft Recipients
S. M. Flechner et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial
Matthew R. Weir et al.
KIDNEY INTERNATIONAL (2011)
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial
Klemens Budde et al.
LANCET (2011)
Results of a Prospective Randomized Trial of Sirolimus Conversion in Kidney Transplant Recipients on Early Corticosteroid Withdrawal
Raymond. L. Heilman et al.
TRANSPLANTATION (2011)
Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus: A Randomized, Multicenter, 24-Month Study
Hallvard Holdaas et al.
TRANSPLANTATION (2011)
Conversion to Low-Dose Tacrolimus or Rapamycin 3 Months After Kidney Transplantation: A Prospective, Protocol Biopsy-Guided Study
O. Pankewycz et al.
TRANSPLANTATION PROCEEDINGS (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Everolimus Plus Reduced-Exposure CsA versus Mycophenolic Acid Plus Standard-Exposure CsA in Renal-Transplant Recipients
H. Tedesco Silva et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2010)
Reduction in Cardiovascular Death After Kidney Transplantation
Helen Pilmore et al.
TRANSPLANTATION (2010)
Renal Function, Efficacy, and Safety of Sirolimus and Mycophenolate Mofetil After Short-Term Calcineurin Inhibitor-Based Quadruple Therapy in De Novo Renal Transplant Patients: One-Year Analysis of a Randomized Multicenter Trial
Markus Guba et al.
TRANSPLANTATION (2010)
Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept Study
Y. Lebranchu et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Monotherapy rapamycin allows an increase of CD4+ CD25bright+ FoxP3+ T cells in renal recipients
Thijs K. Hendrikx et al.
TRANSPLANT INTERNATIONAL (2009)
Contrast Enhanced Sonography Shows Superior Microvascular Renal Allograft Perfusion in Patients Switched From Cyclosporine A to Everolimus
Lars P. Kihm et al.
TRANSPLANTATION (2009)
Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial
Francesco P. Schena et al.
TRANSPLANTATION (2009)
Renal Function Outcomes in Kidney Transplant Recipients After Conversion to Everolimus-Based Immunosuppression Regimen with CNI Reduction or Elimination
A. Cataneo-Davila et al.
TRANSPLANTATION PROCEEDINGS (2009)
Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients
Joerg Seckinger et al.
JOURNAL OF HYPERTENSION (2008)
Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy
Paola Pontrelli et al.
TRANSPLANTATION (2008)
Poor tolerance of sirolimus in a steroid avoidance regimen for renal transplantation
Matthew P. Welberry Smith et al.
TRANSPLANTATION (2008)
The effect of sirolimus in the development of chronic allograft nephropathy
A. Gurkan et al.
TRANSPLANTATION PROCEEDINGS (2008)
Immunosuppression in renal transplantation: some aspects for the modern era
Steven Chadban et al.
Transplantation Reviews (2008)
Reduced exposure to calcineurin inhibitors in renal transplantation
Henrik Ekberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sirolimus versus cyclosporine in kidney recipients receiving Thymoglobulin®, mycophenolate mofetil and a 6-month course of steroids
M. Buechler et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy
M. Liu et al.
TRANSPLANTATION PROCEEDINGS (2007)
Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR study
H. Ekberg et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Sirolimus interferes with iron homeostasis in renal transplant recipients
Annamaria Maiorano et al.
TRANSPLANTATION (2006)
Target of rapamycin inhibitors (Sirolimus and Everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials
Angela C. Webster et al.
TRANSPLANTATION (2006)
Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients
G Stallone et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function
G Russ et al.
TRANSPLANTATION (2005)
A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation
CJE Watson et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study
D Abramowicz et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study
B Nashan et al.
TRANSPLANTATION (2004)
Medical progress - Strategies to improve long-term outcomes after renal transplantation
M Pascual et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
